Research report on global pain management devices market

Published on December 27, 2013 at 4:58 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/26klw6/pain_management) has announced the addition of the "Global Pain Management Devices Market Report 2013-2018 " report to their offering.

The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics.

The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations.

Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market.

Key Topics Covered:

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Pain Management - Types of Treatments
3.2 World Health Organization's Pain Ladder for cancer
3.3 Market Trends and Future Outlook
3.4 Market Drivers
3.5 Market Restraints
3.6 Market Opportunities
3.7 Porter's Five Forces Analysis
3.8 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 Global Pain Management Therapeutics Market, by Therapeutic Class
4.1 Anticonvulsants
4.2 Antidepressants
4.3 Anesthetics
4.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.5 Opioids
4.6 Anti-Migraine Agents
4.7 Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 Global Pain Management Therapeutics Market, by Indication
5.1 Neuropathic Pain
5.2 Fibromyalgia
5.3 Arthritic Pain
5.4 Chronic Back Pain
5.5 Migraine
5.6 Post-operative pain
5.7 Cancer Pain

Chapter 6 Global Pain Management Therapeutics Market, by Geography
6.1 Overview
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World (RoW)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Pain Management Therapeutics Market (2011)
7.2 Pipeline Snapshot: Pain Management Therapeutics

Chapter 8 Recommendations
8.1 Development of novel combination formulations
8.2 Addressing unmet needs: drug abuse and side-effects
8.3 Generics manufacturers: Investment in emerging markets such as India, China and Russia
8.4 Mergers and acquisitions to enter or strengthen market presence

Chapter 9 Company Profiles

Companies Mentioned:

  • Abbott Laboratories
  • Allergan, Inc
  • Covidien plc
  • Durect Corporation
  • Eli Lilly and Company
  • Endo Health Solutions, Inc
  • Forest Laboratories, Inc
  • GlaxoSmithKline plc
  • Hospira, Inc
  • Johnson & Johnson
  • Merck & Co, Inc
  • Mundipharma International Ltd
  • Novartis International AG
  • NuPathe, Inc
  • Pain Therapeutics, Inc
  • Pfizer, Inc
  • Purdue Pharma LP
  • QRx Pharma Ltd
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • UCB (Union Chemnique Belge) SA
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Study shows new role for protein APC in suppressing colorectal cancer